CDK 4/6 inhibitor induced lung injury: a case report and review of literature

Palbociclib is a cyclin dependent kinase (CDK) 4/6 inhibitor that is indicated in combination with an aromatase inhibitor for first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2 -negative advanced or metastatic breast cancer. The commonly described side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Namrata, Joel, Anjana, Andrews, Anand George, John, Ajoy Oommen, Singh, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241445/
https://www.ncbi.nlm.nih.gov/pubmed/34267801
http://dx.doi.org/10.3332/ecancer.2021.1245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241445/
https://www.ncbi.nlm.nih.gov/pubmed/34267801
http://dx.doi.org/10.3332/ecancer.2021.1245

Ejemplares similares